Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016


  • Products Id :- GMDHC0519TDB
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016', provides in depth analysis on Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted pipeline therapeutics.

The report provides comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)

- The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Overview 7

Therapeutics Development 8

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Stage of Development 8

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Therapy Area 9

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Indication 10

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Companies 13

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Universities/Institutes 15

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development 24

Astraea Therapeutics, LLC 24

Grunenthal GmbH 25

Serodus ASA 26

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles 27

AT-076 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

AT-089 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

AT-127 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

AT-212 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

AT-326 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

AT-403 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

cebranopadol - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

GRTTA-2210 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Peptides to Agonize ORL1 for Pain - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

RO-656570 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

SER-100 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Projects 42

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products 43

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Featured News & Press Releases 44

May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile 44

Apr 18, 2016: PCT SER100 patent application filed - Serodus demonstrates a novel mechanism of action in Pulmonary Hypertension 45

Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms 45

Apr 20, 2015: Provisional patent application filed for the Orphan Diseases of Pulmonary Hypertension 46

Sep 15, 2014: Serodus announces details on the clinical study of SER100 in patients with systolic hypertension 46

Sep 09, 2014: Serodus Announces Positive Phase IIa Clinical Study Results On SER100 In Patients with Systolic Hypertension 47

Jun 23, 2014: Serodus Completes The Enrollment Of Patients In Phase IIa Study 47

Nov 05, 2013: Serodus Enrolls First Patient in SER100 Phase IIa Isolated Systolic Hypertension Clinical Study 47

Apr 03, 2013: Serodus Receives Notice Of Allowance For Canadian Patent Covering SER100 48

Jan 11, 2011: Serodus Receives Patent For SER100 In Japan 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Astraea Therapeutics, LLC, H2 2016 24

Pipeline by Grunenthal GmbH, H2 2016 25

Pipeline by Serodus ASA, H2 2016 26

Dormant Projects, H2 2016 42

Discontinued Products, H2 2016 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Astraea Therapeutics, LLC

Grunenthal GmbH

Serodus ASA

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Therapeutic Products under Development, Key Players in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Therapeutics, Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Pipeline Overview, Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Pipeline, Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Pipeline Assessment

select a license

Single User License
USD 3500 INR 236075
Site License
USD 7000 INR 472150
Corporate User License
USD 10500 INR 708225

NEWSLETTER BY CATEGORY




Testimonials

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com